Alpha Tau Medical is an Israeli medical device company that focuses on research, development, and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer. The Alpha DaRT technology was developed in 2003 at Tel Aviv University.
Since then, numerous preclinical trials have found the technology to be effective and safe for various indications and anatomic areas. The findings were published in 12 papers in peer-reviewed scientific journals.
Today, the company is running its first clinical trial with very promising preliminary results.
Since then, numerous preclinical trials have found the technology to be effective and safe for various indications and anatomic areas. The findings were published in 12 papers in peer-reviewed scientific journals.
Today, the company is running its first clinical trial with very promising preliminary results.
Location: United States, Massachusetts, Lawrence
Employees: 51-200
Phone: +972 58-682-1373
Total raised: $55M
Founded date: 2016
Investors 5
| Date | Name | Website |
| 04.12.2023 | Deep Insig... | deepinsigh... |
| - | Medison Ve... | medisonven... |
| - | Shavit Cap... | shavitcapi... |
| - | MUUS Clima... | muus.com |
| - | Arc Ventur... | arc-vc.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.06.2020 | - | $26M | - |
| 09.09.2018 | - | $29M | - |
Mentions in press and media 22
| Date | Title | Description |
| 16.08.2024 | From Comfort to Cure’: Answering the Call of ASCO 2024 | Dr. Robert Den, Chief Medical Officer at Alpha Tau Medical The landscape of cancer treatment has continued to evolve, and the annual ASCO Meetings often set the stage for “what’s next in cancer care.” The overarching narrative at the 2024 A... |
| 07.03.2024 | Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update | - |
| 22.05.2023 | Новая лучевая терапия рака убивает опухоли изнутри | Новая лучевая терапия рака, которая воздействует на опухоли изнутри с помощью альфа-частиц, в настоящее время находится на этапе 3 основных испытаний перед получением одобрения Управления по санитарному надзору за качеством пищевых продукто... |
| 20.01.2022 | Alpha Tau Announces New Research Collaboration to Study the Potential of Alpha DaRT to Enhance Immune Stimulation in the Treatment of Breast Cancer | JERUSALEM, Jan. 20, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has signed a sponsored research agreement with inve... |
| 10.01.2022 | Alpha Tau Announces Results of First US Clinical Trial of Alpha DaRT™ in Malignant Skin & Soft Tissue Cancers, Showing Complete Response in All Ten Treated Tumors at Approximately 12 Weeks and No ... | JERUSALEM, Jan. 10, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that all ten patients in its US multi-center pilot trial of... |
| 03.01.2022 | Alpha Tau Announces Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck Cancer | JERUSALEM, Jan. 3, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has been notified by HekaBio K.K., its clinical tria... |
| 03.11.2021 | Alpha Tau Announces Enrollment of First Patient in Combination Trial of Alpha DaRT™ and Pembrolizumab (Keytruda®) | JERUSALEM, Nov. 3, 2021 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that it has enrolled its first patient in the combination stu... |
| 25.10.2021 | Healthcare Capital : Alpha Tau Announces Completion of Enrollment in First US Clinical Trial of Alpha DaRT™ and Achievement of First Primary Objective | JERUSALEM, Oct. 25, 2021 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that its US pilot trial for skin cancer has completed enroll... |
| 08.10.2021 | Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM | JERUSALEM, Oct. 8, 2021 /PRNewswire/ -- Alpha Tau Medical, the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, is pleased to announce that it has received Breakthrough Device Designation for Alpha DaRT from the U.S. ... |
| 16.07.2021 | Cancer therapy startup Alpha Tau to go public with USD 1 billion valuation | Alpha Tau Medical, an Israeli medical technology company that developed breakthrough radiation cancer therapy, announced this month that it had entered into an agreement with special purpose acquisition company Healthcare Capital Corp (HCC)... |
Show more